Uppsala, Sweden – May 15, 2020 – Orexo´s partner, Gesynta Pharma,  today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions. The purpose of the first clinical study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI (GS-248) after single and multiple ascending doses to healthy subjects.

The results support further clinical development of OX-MPI (GS-248) and a clinical phase II study is being planned.

The study will be presented at the 2020 EULAR e-congress June 3-6.

For more information read Gesynta Pharma´s press release attached below.